OncoImmunology · 2013 · 43 citations · 13 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCancer VaccinesCell-based ImmunotherapyDendritic Cell BiologyImmunotherapy For Solid TumorsTumor-associated AntigensAnticancer ActivityAntitumor Immune ActivationCross-presentation In Cancer VaccinationDendritic Cell Antigen ProcessingDendritic Cell EngineeringMhc Class I MoleculesTumor Antigen-based ImmunotherapyWhole-cell Cancer Vaccines
Various strategies have been developed to deliver tumor-associated antigens (TAAs) to dendritic cells (DCs). Among these, the fusion of DCs and whole cancer cells can process a broad array of TAAs, including hitherto unidentified molecules, and present them in complex with MHC Class I and II molecules and in the context of co-stimulatory signals. DC-cancer cell fusions have been shown to stimulate potent antitumor immune responses in animal models. In early clinical trials, however, the antitumor effects of DC-cancer cell fusions are not as vigorous as in preclinical settings. This mini-review summarizes recent advances in anticancer vaccines based on DC-cancer cell fusions.
13
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Frank O. Nestlé, Selma Alijagic, Michel Gilliet et al. · Nature Medicine · 1998 · 2.9K citations
Medicine, Immunology, Oncology +14